Sarcoidosis
BLOG: Saving lives in the eye clinic
My residency director, David Carey, used to say ironically, “If you step back and take a careful look, you’ll see there’s a whole patient behind that eyeball.”
Fewer than 50% of patients with sarcoidosis treated within year of diagnosis
Less than half of patients with sarcoidosis had been treated by the 1-year mark since being diagnosed with the condition, according to results published in CHEST.
Rheumatologists should play ‘active role’ in sarcoidosis management
SAN DIEGO — Rheumatologists may be the best clinicians to manage the challenges presented by sarcoidosis, which include a complex disease course and few treatment options, said a presenter at the 2024 Congress of Clinical Rheumatology West.
‘A lot of unknowns’: Much remains a mystery regarding sarcoidosis etiology, management
ORLANDO, Fla. — Despite a constellation of available data points regarding prognosis and impacted organs, researchers have so far been unable to connect the dots and form a better understanding of sarcoidosis, according to a presenter here.
Man referred for medication monitoring without ocular symptoms
A 75-year-old man was referred to the retina service by his comprehensive ophthalmologist for high-risk medication monitoring. The patient denied acute ocular symptoms such as vision loss, flashes, floaters or eye pain.
Several environmental exposures raise risk for sarcoidosis in African Americans
Exposure to mold/musty odors, various metals and farm animals raised the odds for sarcoidosis in African Americans, according to results published in Annals of the American Thoracic Society.
Blood test demonstrates high accuracy in identifying sarcoidosis
A blood test was capable of distinguishing sarcoidosis from other respiratory diseases using disease-specific antigen biomarkers/epitopes, according to results published in American Journal of Respiratory and Critical Care Medicine.
Efficacy, safety outcomes similar with high, low prednisolone dose for sarcoidosis
Patients with sarcoidosis receiving 40 mg per day of prednisolone had comparable rates of treatment failure and adverse effects to patients receiving 20 mg per day, according to a European Respiratory Society International Congress presentation.
Efzofitimod safe, may improve clinical outcomes in patients with sarcoidosis
Among patients with pulmonary sarcoidosis, efzofitimod was safe through 24 weeks, and it improved measures of lung function and quality of life when given at a higher dosage, according to study results published in CHEST.
Sarcoidosis diagnostic scores have ‘good to excellent’ discriminatory ability
The ability to discern sarcoidosis from other diagnoses was “good to excellent” in two sarcoidosis diagnostic scores, according to results published in Annals of the American Thoracic Society.